Clinical Trial: Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235033) titled 'Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)' on Nov. 14.

Brief Summary: This is Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria

Study Start Date: Jan. 23, 2024

Study Type: INTERVENTIONAL

Condition: Uncomplicated Plasmodium Falciparum Malaria

Intervention: DRUG: Cipargamin

oral capsules administered in combination with KLU156

DRUG: SoC (Coartem)

Standard of Care (Coartem)

DRUG: KLU156

oral sachet ...